The Latest
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Electra Therapeutics, a former subsidiary of the hub-and-spoke biotechnology firm Star Therapeutics, is the latest immune disease-focused drugmaker to pursue an initial public offering, according to a Friday regulatory filing.
Updated Aug. 28, 2026 -
Permission granted by Verily Health
Sponsored by Verily HealthThe next frontier: Advancing foundation models with multimodal data
What's possible when AI models can learn from additional health data modalities to create a more complete understanding of human health?
-
Jacob Bell/BioPharma Dive
FDA OKs Takeda, Protagonist drug for rare blood cancer
The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.
-
Getty Images
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
-
Courtesy of Priovant Therapeutics
FDA green lights Priovant drug for rare skin disease
Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.
Updated Aug. 28, 2026 -
Permission granted by Outer Bio
Q&A // Emerging biotechMichael Polansky has a new, skin-focused biotech. Don’t call it a drug company.
Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious about steering clear of road bumps that slow biotechs.
-
Getty Images
Emerging biotechWill a ‘reset’ reignite investment in women’s health startups?
After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI and a widening definition of what constitutes women’s health could spur a rebound, some say.
-
Getty Images
News roundupModerna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
-
Alamy
New data could widen use of AstraZeneca, Amgen immune disease drug
Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.
-
Courtesy of Revolution Medicines
Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA
Rasonque’s speedy approval — just a month after a completed submission — represents a paradigm shift for a notoriously deadly cancer and begins what analysts see as a highly lucrative drug launch.
Updated Aug. 27, 2026 -
Courtesy of Biohaven Ltd.
Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal
Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a “surprising” transaction.
-
Getty Images
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.
-
Karissa Waddick/Industry Dive
Emerging biotechYoung startups miss out on biotech venture funding rebound, MassBio says
A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions, as funding slows for young companies with the “riskiest science.”
-
Getty Images
News roundup
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
-
Getty Images
New Jazz cancer drug approval could drive blockbuster sales
Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
-
Permission granted by Cellares
Emerging biotechCellares, a cell therapy manufacturing specialist, to lay off 100 employees
The restructuring comes after an unnamed "large pharmaceutical customer" terminated a contract with the company, Cellares CEO Fabian Gerlinghaus posted on LinkedIn.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Following a $1.5 billion licensing deal with stealthy startup Sentivera, Haisco Pharmaceutical now ranks among the sector's most prolific China-based partners since the start of 2025, BioPharma Dive data show.
Updated Aug. 25, 2026 -
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test
Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.
-
Sarah Silbiger via Getty Images
Safety concerns spur FDA to again halt testing of Regenxbio gene therapy
Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.
-
Permission granted by Roche
Obesity drugsRoche commits to lean-mass preservation with Hanmi obesity deal
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
-
Getty Images
Obesity drugsHow cost and perception could reshape the GLP-1 market
As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.
-
Getty Images
VaccinesCancer vaccine win restores Wall Street’s faith in Moderna
Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet.
-
Getty Images
News roundup
FDA extends review of Capricor cell therapy; Pain drug startup to go public
The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
So far in 2026, RA Capital and OrbiMed again rank as the most active investors tracked by BioPharma Dive. But multiple corporate venture arms are in the top 10 this year as well.
Updated Aug. 13, 2026 -
Getty Images
Regeneron to challenge Ipsen as FDA clears bone disease drug
Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.
-
Sundry Photography via Getty Images
Ultragenyx, after setbacks, nabs first gene therapy approval
The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.
